Replimune Investors Brace for Volatility as FDA Verdict Looms

Investors hedge heavily as the FDA's final decision on Replimune's melanoma therapy RP1 nears, following a 2025 rejection and a stock plunge. The company has $269M cash runway.

The options market is flashing a clear warning sign ahead of the US Food and Drug Administration's final verdict on Replimune's lead cancer therapy, RP1. Trading activity in put options surged by 29% above normal levels on Thursday, with nearly 3,900 contracts purchased, signaling widespread investor hedging against a potential stock decline following the regulatory decision.

This pivotal moment comes more than a year after the FDA issued a Complete Response Letter rejecting RP1's initial application in July 2025. The agency's substantive critique centered on the design of the supporting IGNYTE trial, which it deemed an insufficiently controlled clinical investigation with an overly heterogeneous patient population. Regulatory scrutiny intensified when the FDA's top cancer drug regulator reportedly intervened during the final review phase, a move seen as pivotal to the initial rejection.

Replimune's resubmission aimed to address these concerns head-on, bolstered by data from the Phase 1/2 IGNYTE study involving 140 patients with advanced melanoma who had progressed after prior PD-1 therapy. The data showed an objective response rate of 32.9%, with a subgroup of patients with acral melanoma responding at a rate of 44%. The company explicitly tackled previous regulatory criticisms regarding PD-1 resistance criteria and the use of literature data to support component contributions in its latest filing.

Equity markets have already priced in significant uncertainty. The stock plummeted 15% in a single session earlier this week, sinking to approximately $5.79 and trading roughly 30% below its 100-day moving average. Trading volume spiked ahead of the decision, with over 2.3 million shares changing hands, well above the daily average. On social investment platforms, discussion activity rocketed 171% higher over seven days as overall sentiment shifted from bullish to neutral.

Financially, Replimune enters this critical juncture with a solid runway. The company holds cash reserves of approximately $269 million, which management states is sufficient to fund operations into the first quarter of 2027. This buffer provides a contingency plan should the FDA deliver another rejection.

Beyond today's decision, Replimune's clinical pipeline continues to advance. The Phase 3 IGNYTE-3 trial, enrolling around 400 patients with overall survival as the primary endpoint, is actively underway. The company is also progressing the REVEAL study for its RP2 candidate in uveal melanoma. FDA protocols from prior Type-A meetings have indicated that positive data from IGNYTE-3 could potentially support a future approval.

The medical need for new therapies is acute. Patients with advanced melanoma following the failure of a PD-1 blockade have few effective treatment alternatives. Replimune's CEO has noted that clinicians and patient advocacy groups have voiced strong support for access to RP1.

While some investors noted recent insider selling by the chief commercial officer, that transaction involved 6,500 shares sold at an average price of $8.01 under a pre-arranged trading plan established in December 2025. Such automated sales are routine and the executive retains a substantial stake of over 150,000 shares.

Wall Street analysts maintain an average price target of $12.86 for the stock, implying significant upside. However, as one retail investor succinctly noted on Stocktwits, the equity faces a binary outcome: it could triple in value or lose the majority of its worth based solely on the content of the FDA's document released later today.